1. Home
  2. WVE vs DXC Comparison

WVE vs DXC Comparison

Compare WVE & DXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$7.07

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Logo DXC Technology Company

DXC

DXC Technology Company

HOLD

Current Price

$8.96

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
WVE
DXC
Founded
2012
1959
Country
Singapore
United States
Employees
N/A
115000
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.1B
IPO Year
2015
2016

Fundamental Metrics

Financial Performance
Metric
WVE
DXC
Price
$7.07
$8.96
Analyst Decision
Strong Buy
Hold
Analyst Count
16
7
Target Price
$29.81
$15.00
AVG Volume (30 Days)
3.9M
4.0M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.10
Revenue
$3,704,000.00
$12,644,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$85.67
N/A
P/E Ratio
N/A
$94.05
Revenue Growth
149.43
N/A
52 Week Low
$5.02
$8.40
52 Week High
$21.73
$17.14

Technical Indicators

Market Signals
Indicator
WVE
DXC
Relative Strength Index (RSI) 39.03 29.04
Support Level $6.81 N/A
Resistance Level $7.67 $15.25
Average True Range (ATR) 0.36 0.67
MACD 0.15 -0.27
Stochastic Oscillator 28.00 10.28

Price Performance

Historical Comparison
WVE
DXC

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About DXC DXC Technology Company

DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.

Share on Social Networks: